Switzerland-based Basilea Pharmaceutica has begun a new pharmacokinetic Phase I study of antibiotic BAL30072 in healthy volunteers.

BAL30072 is an injectable sulfactam antibiotic with the potential to target clinically relevant multidrug-resistant gram-negative bacteria including Pseudomonas or Acinetobacter.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The antibiotic is designed to tackle several resistance mechanisms adopted by bacterial species.

"BAL30072 is an injectable sulfactam antibiotic with the potential to target clinically relevant multidrug-resistant gram-negative bacteria including Pseudomonas or Acinetobacter."

Basilea chief medical officer Professor Achim Kaufhold said; "Due to its potent antimicrobial activity BAL30072 has the potential to play an essential role in the therapy of serious and life-threatening infections caused by Gram-negative bacteria for which currently only limited therapeutic options exist.

"We are now expanding our Phase I clinical program for this promising drug candidate to optimise dosing regimens in preparation for Phase II clinical studies."

See Also:

BAL30072 cannot be readily destroyed by bacterial enzymes, which cause resistance to many marketed antibiotics, such as extended-spectrum beta-lactamases (ESBLs), carbapenemases or the New Delhi metallo-beta-lactamase 1 (NDM-1).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Gram-negative pathogens are the major cause for hospital-acquired bacterial infections, and many of them have developed resistance towards antibiotics by producing various enzymes.

Multidrug-resistant bacteria are the main cause to increased mortality, prolonged hospital stays and higher healthcare costs.